Lipid Formulations in Customized Enteric Capsules Show Promising Results For Oral GLP-1 RA Delivery
Wednesday, July 16, 2025
3:38 PM - 3:49 PM EDT
Location: 124
Introduction: Oral delivery of GLP-1 receptor agonists would offer a life-changing solution for patients suffering from Type 2 diabetes. However enzymatic degradation and gastrointestinal permeation result in low oral bioavailability of these drug modalities. This study aims to combine Hydrophobic Ion Pairing (HIP), Lipid-Based Formulation (LBF), Permeation Enhancer (PE) with a customized compatible enteric capsule to address above limitations, using Exenatide (EXE) as model GLP-1 RA.
Learning Objectives:
At the completion of this activity, participants will know
Demonstrate performance of enteric capsules filled with Lipid Formulation and Permeation Enhancer.
Vanessa Gonzalez, Ms – Scientist, Capsugel France SAS / Lonza; Sandrine Picco, Ms – Analytical Dev. Lead, Capsugel France SAS / Lonza; Marine Agisson, Ms – Scientist, Capsugel France SAS / Lonza; Pierre Verlhac, Dr – Scientist, Capsugel France SAS / Lonza; Delphine Nombret, Ms – Sr Scientist, Capsugel France SAS / Lonza; Camille Dumont, Dr – Manager, Capsugel France SAS / Lonza
